KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash & Current Investments (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Cash & Current Investments readings, the most recent being $185.2 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 42.27% to $185.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $185.2 million, a 42.27% decrease, with the full-year FY2025 number at $185.2 million, down 42.27% from a year prior.
  • Cash & Current Investments hit $185.2 million in Q4 2025 for Biocryst Pharmaceuticals, up from $129.4 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $507.6 million in Q4 2021 to a low of $4.3 million in Q3 2021.
  • Median Cash & Current Investments over the past 5 years was $257.1 million (2023), compared with a mean of $234.4 million.
  • Biggest five-year swings in Cash & Current Investments: plummeted 91.24% in 2021 and later soared 4122.6% in 2022.
  • Biocryst Pharmaceuticals' Cash & Current Investments stood at $507.6 million in 2021, then decreased by 16.41% to $424.3 million in 2022, then dropped by 8.32% to $389.0 million in 2023, then decreased by 17.52% to $320.8 million in 2024, then tumbled by 42.27% to $185.2 million in 2025.
  • The last three reported values for Cash & Current Investments were $185.2 million (Q4 2025), $129.4 million (Q3 2025), and $172.5 million (Q2 2025) per Business Quant data.